2.35
price down icon1.26%   -0.03
 
loading
Jaguar Health Inc stock is traded at $2.35, with a volume of 27,156. It is down -1.26% in the last 24 hours and down -22.95% over the past month. Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
See More
Previous Close:
$2.38
Open:
$2.38
24h Volume:
27,156
Relative Volume:
0.19
Market Cap:
$3.83M
Revenue:
$10.48M
Net Income/Loss:
$-37.74M
P/E Ratio:
-0.1452
EPS:
-16.1846
Net Cash Flow:
$-29.03M
1W Performance:
+1.29%
1M Performance:
-22.95%
6M Performance:
-89.06%
1Y Performance:
-93.33%
1-Day Range:
Value
$2.33
$2.40
1-Week Range:
Value
$2.27
$2.44
52-Week Range:
Value
$2.27
$35.25

Jaguar Health Inc Stock (JAGX) Company Profile

Name
Name
Jaguar Health Inc
Name
Phone
415-371-8300
Name
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Name
Employee
49
Name
Twitter
@Jaguar_Health
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
JAGX's Discussions on Twitter

Compare JAGX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
JAGX
Jaguar Health Inc
2.35 3.18M 10.48M -37.74M -29.03M -16.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.50 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
567.54 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.83 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
588.88 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.00 31.99B 3.81B -644.79M -669.77M -6.24

Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-07-21 Initiated Cantor Fitzgerald Overweight
Jul-11-17 Initiated Rodman & Renshaw Buy

Jaguar Health Inc Stock (JAGX) Latest News

pulisher
Jul 23, 2025

What drives Jaguar Health Inc. stock priceExplosive market performance - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs - Sentinel-Standard

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Jaguar Health Inc. stockSkyrocketing investment returns - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Jaguar Health Inc. Stock Analysis and ForecastAccelerated investment success - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Jaguar Health Inc. a good long term investmentTremendous return rates - Autocar Professional

Jul 22, 2025
pulisher
Jul 21, 2025

Form DEF 14A Jaguar Health, Inc. For: Aug 19 - StreetInsider

Jul 21, 2025
pulisher
Jul 20, 2025

Published on: 2025-07-20 16:31:40 - Autocar Professional

Jul 20, 2025
pulisher
Jul 16, 2025

Jaguar Health Announces Amendment to March 2020 Equity Purchase Agreement with Oasis Capital, LLC - FinancialContent

Jul 16, 2025
pulisher
Jul 10, 2025

Clinical Trial Launches for First FDA-Approved Dog Diarrhea Treatment, Targeting $6B Pet Health Market - Stock Titan

Jul 10, 2025
pulisher
Jul 09, 2025

Jaguar Health Eliminates Certain Royalty Obligations Reducing Future COGS for Mytesi and Crofelemer - ACCESS Newswire

Jul 09, 2025
pulisher
Jul 08, 2025

Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS In - El Paso Times

Jul 08, 2025
pulisher
Jul 08, 2025

Groundbreaking Deal: Peru Grants Access to Sacred Coca Plant for Mental Health Drug Research - Stock Titan

Jul 08, 2025
pulisher
Jul 07, 2025

Investors Give Jaguar Health, Inc. (NASDAQ:JAGX) Shares A 36% Hiding - 富途牛牛

Jul 07, 2025
pulisher
Jul 05, 2025

Jaguar Health Announces that Orphan Drug Designation Application Submitted to the FDA for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Has Been Accepted for Review - ACCESS Newswire

Jul 05, 2025
pulisher
Jul 04, 2025

Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Lohud

Jul 04, 2025
pulisher
Jul 02, 2025

Investors Give Jaguar Health, Inc. (NASDAQ:JAGX) Shares A 43% Hiding - simplywall.st

Jul 02, 2025
pulisher
Jun 30, 2025

Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient - Worcester Telegram

Jun 30, 2025
pulisher
Jun 30, 2025

Breakthrough Treatment Reduces Parenteral Nutrition by 27% in Orphan Disease PatientsNew Clinical Data - Stock Titan

Jun 30, 2025
pulisher
Jun 27, 2025

Jaguar Health (JAGX) Announces $3.37M At-The-Market Stock Offering | JAGX SEC FilingForm 424B5 - Stock Titan

Jun 27, 2025
pulisher
Jun 26, 2025

Jaguar Health (JAGX) Adopts Cryptocurrency as Treasury Asset | JAGX Stock News - GuruFocus

Jun 26, 2025
pulisher
Jun 26, 2025

Jaguar Health considers cryptocurrency for treasury reserves - Investing.com

Jun 26, 2025
pulisher
Jun 25, 2025

Jaguar Health (JAGX) Targets EU Approval for Canalevia in Dogs | - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Jaguar Health (JAGX) Targets EU Approval for Canalevia in Dogs | JAGX Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Jaguar Health seeks EU approval for dog diarrhea treatment - Investing.com

Jun 25, 2025
pulisher
Jun 24, 2025

Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026 - The Columbus Dispatch

Jun 24, 2025
pulisher
Jun 24, 2025

Jaguar Health extends maturity date for $2.57 million in notes By Investing.com - Investing.com Nigeria

Jun 24, 2025
pulisher
Jun 23, 2025

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer - The Holland Sentinel

Jun 23, 2025
pulisher
Jun 23, 2025

Jaguar Health reports 25% enrollment in phase 2 MVID study - Investing.com

Jun 23, 2025
pulisher
Jun 18, 2025

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts - Marco Eagle

Jun 18, 2025

Jaguar Health Inc Stock (JAGX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.61
price up icon 3.24%
$36.53
price up icon 1.47%
$103.71
price up icon 0.18%
$27.51
price down icon 1.96%
$114.46
price down icon 0.09%
biotechnology ONC
$296.00
price up icon 0.50%
Cap:     |  Volume (24h):